降钙素基因相关肽受体拮抗剂ubrogepant 治疗急性偏头痛的Meta 分析。

Calcitonin gene-related peptide receptor antagonist ubrogepant for the treatment of acute migraine: A meta-analysis.

机构信息

School of Pharmacy, Southwest Medical University, Luzhou Sichuan.

School of Pharmacy, North Sichuan Medical College, Nanchong Sichuan.

出版信息

Medicine (Baltimore). 2021 Feb 26;100(8):e24741. doi: 10.1097/MD.0000000000024741.

DOI:10.1097/MD.0000000000024741

PMID:33663087

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7909234/

Abstract

BACKGROUND

The objective of this study is to systematically evaluate the efficacy and safety of the calcitonin gene-related peptide (CGRP) receptor antagonist ubrogepant for the treatment of acute migraine.

METHODS

Randomized controlled trials (RCTs) of ubrogepant for treatment of acute migraine were identified in PubMed, MEDLINE, EMBASE, and the Cochrane Library from database establishment to June 2020; we also searched ClinicalTrials.gov manually during the same period. Then, RevMan 5.3 software was used to perform a meta-analysis on each outcome measure.

RESULTS

A total of 5 RCTs involving 4903 patients were included; there were 3358 cases in the ubrogepant group and 1545 cases in the placebo group. The meta-analysis showed the following results: at 2 hours postdose, the percentages of participants reporting pain relief and the absence of photophobia, nausea, and phonophobia were significantly higher in the ubrogepant group than in the placebo group (odds ratio [OR] = 1.71, 95%CI: 1.48-1.97, P < .00001; OR = 1.33, 95%CI: 1.22-1.45, P < .00001; OR = 1.07, 95%CI: 1.03-1.11, P = .0006; OR = 1.21, 95%CI: 1.14-1.28, P < .00001). The incidence of common adverse events was similar between the 2 groups (P > .05).

CONCLUSION

Ubrogepant is effective and safe for the treatment of acute migraine.

REGISTRATION NUMBER

PROSPERO CRD42019145286.

摘要

背景

本研究旨在系统评估降钙素基因相关肽（CGRP）受体拮抗剂ubrogepant 治疗急性偏头痛的疗效和安全性。

方法

从数据库建立到 2020 年 6 月，我们在 PubMed、MEDLINE、EMBASE 和 Cochrane Library 中检索了 ubrogepant 治疗急性偏头痛的随机对照试验（RCT）；同期，我们还在 ClinicalTrials.gov 上手动检索。然后，我们使用 RevMan 5.3 软件对每个结局指标进行荟萃分析。

结果

共纳入 5 项 RCT，涉及 4903 例患者；ubrogepant 组 3358 例，安慰剂组 1545 例。荟萃分析结果显示：给药后 2 小时，ubrogepant 组报告疼痛缓解和无畏光、恶心和恐声的患者比例显著高于安慰剂组（比值比[OR] = 1.71，95%CI：1.48-1.97，P <.00001；OR = 1.33，95%CI：1.22-1.45，P <.00001；OR = 1.07，95%CI：1.03-1.11，P = 0.0006；OR = 1.21，95%CI：1.14-1.28，P <.00001）。两组常见不良反应发生率相似（P >.05）。